#United States #Minneapolis #Heart Failure #HFSA #Clinical Research

Late Breaking Clinical Research at HFSA Annual Scientific Meeting

The Heart Failure Society of America (HFSA) is gearing up for an exciting Annual Scientific Meeting (ASM) where it will showcase significant findings from late breaking clinical research. Scheduled to take place from September 26 to 29, 2025, at the Minneapolis Convention Center in Minneapolis, MN, this conference promises to unveil the latest advancements in heart failure management and therapies.

Overview of the Event

The HFSA ASM serves as a key gathering for heart failure specialists from across various fields, providing a unique platform for sharing breakthroughs and advancements in research. This year, attendees can expect two key plenary sessions dedicated to presenting late breaking clinical trials and research results that could significantly impact patient care and treatment methods.

During the plenary sessions, the latest findings from major randomized trials will be highlighted. These sessions are pivotal, showcasing research that advances our understanding of heart failure treatment and technologies.

Key Presentations and Trials

Among the featured trials on Sunday, September 28, the first plenary session will discuss devices and cardiomyopathies, including:

• - Integra-D Trial: This research evaluates the effects of a novel Cardiac Contractility Modulation-Defibrillator (CCM-D) on patients who have an Implantable Cardioverter-Defibrillator (ICD) and are looking at their NYHA Functional Class post-implant.
• - FUTURE-HF Trial: Focused on an individualized congestion scoring system utilizing a new implantable inferior vena cava sensor.
• - DETECT-HF Trial: This exciting study involves a voice-based algorithm for heart failure monitoring, validated across 599 patients.
• - FOREST-HCM Study: Evaluation of the safety and efficacy of Aficamten in patients suffering from non-obstructive hypertrophic cardiomyopathy.
• - MAPLE-HCM Trial: Examines the divergent effects of Aficamten compared to Metoprolol in obstructive hypertrophic cardiomyopathy.
• - ATTRibute-CM Study: This research highlights the early reduction in cardiovascular outcomes with Acoramidis in patients with transthyretin amyloid cardiomyopathy.
• - HELIOS-B Trial: Analyzes the gastrointestinal event reduction in ATTR-CM patients treated with Vutrisiran versus a placebo.

On Monday, September 29, the focus will shift to novel therapies, covering:

• - VICTOR Trial: Analyzes the efficacy and safety of Vericiguat across various therapeutic backgrounds in ambulatory patients with heart failure with reduced ejection fraction (HFrEF).
• - SEISMiC C Appraisal: This trial looks into the safety and efficacy of intravenous administration of Istaroxime for acute heart failure.
• - SUMMIT Trial: Offers insights into the effects of Tirzepatide on obesity-related heart failure with preserved ejection fraction (HFpEF).

Engaging Rapid Fire Sessions

In addition to the plenary presentations, the HFSA is set to host Rapid Fire Oral Sessions, which will provide a fast-paced platform for researchers to present their latest findings succinctly. These sessions will shine a light on critical data from newly submitted research, helping attendees stay abreast of cutting-edge advancements in the field.

Highlights of Rapid Fire Presentations

• - Phase 1 study exploring Daratumumab-Hyaluronidase for patients awaiting heart transplantation.
• - Safety evaluations of Sodium-Glucose Cotransporter 2 Inhibitors in post-heart transplant patients.
• - Long-term outcomes from LVAD weaning trials and their implications.
• - First-in-human studies of next-generation membrane-based LVADs.
• - Insights into advanced heart failure screening in stable outpatients.

Conclusion

As participants prepare for this anticipated event, they can find more information, including the event schedule and networking opportunities, by visiting the HFSA website. The upcoming HFSA Annual Scientific Meeting promises to be a landmark event in advancing our understanding of heart failure care, showcasing innovative research that could shape future clinical practice.

Don’t miss the chance to engage with leading experts in the field and gain insights into the advanced methodologies and treatments currently under investigation. For registration details and a complete agenda, visit hfsa.org/asm2025.

• ---

The HFSA is committed to fostering innovation, education, and advocacy to enhance care for heart failure patients, serving as a crucial forum for all stakeholders in this vital area of healthcare.